{"id":"NCT01727713","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","briefTitle":"Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder","officialTitle":"An Open-Label, Multicenter Study Evaluating the Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-01","primaryCompletion":"2014-08","completion":"2014-09","firstPosted":"2012-11-16","resultsPosted":"2015-10-16","lastUpdate":"2015-10-16"},"enrollment":110,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Tourette's Disorder","Tic Disorder"],"interventions":[{"type":"DRUG","name":"Aripiprazole","otherNames":["Abilify"]}],"arms":[{"label":"Aripiprazole","type":"EXPERIMENTAL"}],"summary":"The goal of the current trial is to determine safety of Once-daily aripiprazole in reducing Total Tic Severity in children and adolescents with Tourette's Disorder.","primaryOutcome":{"measure":"Percentage of Participants With Adverse Events.","timeFrame":"Baseline, throighout the 52-week treatmetn and 30Â±3 days after last trial visit","effectByArm":[{"arm":"Open-label Aripiprazole","deltaMin":76.4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"7 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":8},"locations":{"siteCount":33,"countries":["United States","Canada","Hungary","Italy"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":110},"commonTop":["Weight increased","Somnolence","Fatigue","Nasopharyngitis","Headache"]}}